AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASCENTAGE PHARMA GROUP INTERNATIONAL
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 29, 2026
$15.36−0.01 (-0.07%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 373M shares
Institutional holders
8
3 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AAPG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13,841 | 0.00% | $243.05K | −2,215 | 0.00% |
| Morgan Stanley | 919 | 0.00% | $16.14K | +421 | 0.00% |
| Wells Fargo & Company/Mn | 200 | 0.00% | $3.51K | New | 0.00% |
| EverSource Wealth Advisors, LLC | 24 | 0.00% | $421 | – | 0.00% |
| UBS Group AG | 15 | 0.00% | $263 | −109 | 0.00% |
| Royal Bank of Canada | 6 | 0.00% | $0 | – | 0.00% |
| BlackRock, Inc. | 6 | 0.00% | $105 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $18 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.0% | 3 / 1 | 2 / 2 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.0% | 0 / 2 | 3 / 5 | 0M | 0M |
| Q4 2025 | 12 | 0M | 0.0% | 2 / 3 | 5 / 3 | 0M | 0M |
| Q3 2025 | 14 | 0M | 0.0% | 6 / 3 | 4 / 4 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.0% | 9 / 1 | 2 / 3 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.1% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AAPG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 361 | 0.00% | $7.26K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dajun Yang | Chairman and CEO, Director | 37,742,091 | 10.11% | May 22, 2026 |
| Faical Miyara | Chief Business Officer | – | – | Jun 29, 2026 |
| Yifan Zhai | Chief Medical Officer | 37,742,091 | 10.11% | May 22, 2026 |
| Veet Misra | Chief Financial Officer | – | – | Apr 21, 2026 |
| Jin Cao | Chief Accounting Officer | 5,400 | 0.00% | Apr 20, 2026 |
| Thomas J. Knapp | SVP/General Counsel | 362,444 | 0.10% | Mar 23, 2026 |
| Shaomeng Wang | Director | 10,053,943 | 2.69% | Mar 23, 2026 |
| Ren Wei | Director | 8,964 | 0.00% | Mar 23, 2026 |
| Marc E. Lippman | Director | 21,174 | 0.01% | Mar 23, 2026 |
| David Sidransky | Director | 10,641 | 0.00% | Mar 23, 2026 |
| Marina Bozilenko | Director | – | – | Mar 23, 2026 |
| Debra Yu | Director | – | – | Mar 23, 2026 |
| Simon Dazhong Lu | Director | 41,457 | 0.01% | Mar 23, 2026 |
| Changqing Ye | Director | 8,964 | 0.00% | Mar 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yifan Zhai Chief Medical Officer | May 21, 2026 | Option exercise | +92,746 | – | – | 405,280 |
| Yifan Zhai Chief Medical Officer | May 21, 2026 | Option exercise | +95,575 | – | – | 1,193,569 |
| Dajun Yang Chairman and CEO, Director | May 21, 2026 | Option exercise | +95,575 | – | – | 1,193,569 |
| Dajun Yang Chairman and CEO, Director | May 21, 2026 | Option exercise | +92,746 | – | – | 405,280 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.